article thumbnail

National variation in ASCVD risk between Pooled Cohort Equations and PREVENT [Cardiovascular disease]

Annals of Family Medicine

Study Design and Analysis This study utilized data from NHANES 2011-2019 to calculate two ASCVD risk scores for each eligible individual: one using the race-based PCE and the other using the race-agnostic PREVENT equation. Each individual was separated into clinically significant risk categories of <7.5%, 7.5-10%, 10%, and >10%.

article thumbnail

Diabetes related complications among Ethiopian Jews-Outcomes of a 10 years cohort study in Israel [Population health and epidemiology]

Annals of Family Medicine

Population: Jewish CHS members, aged 18+, diagnosed with T2D between 2000-2011, born in Israel or Ethiopia. Conclusions: It is imperative to provide specialized care for immigrant populations to enhance the management of chronic diseases and mitigate further morbidity risks. Intervention: 10-year follow-up to track T2D outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Using technology to reclaim our time

Today's Hospitalist

Since the mid-1990s, our capacity for innovation has never stopped as hospitalists navigate a complex landscape of acute illnesses, interprofessional collaborations and the imperative to provide efficient, high-quality care. We have seen explosive growth and become a cornerstone of modern health care systems.

article thumbnail

GeneSight® Mental Health Monitor Results

Myriad Genetics

It’s encouraging to see patients recognize what we, as healthcare providers, already know—that medications can be an effective option for people struggling with depression, anxiety, and other mental health conditions,” said Dr. Brown. He was elected to serve AAPOR as its Vice President, President, and Past President from 2011-2014.

article thumbnail

FDA Flexes its New FDORA Muscles in Withdrawing an Accelerated Approval

FDA Law Blog

This is the third withdrawal of an accelerated approval FDA has performed, following Avastin in 2011 and Makena in 2023. Prior to FDORA’s enactment, the statute did not provide details on the withdrawal procedures other than offering an opportunity for an informal hearing. Tobolowsky & Michelle L.

IT 59
article thumbnail

Every Day Counts for PTE: Court Finds FDA’s Reinterpretation of Testing Phase Arbitrary and Capricious

FDA Law Blog

Patent and Trademark Office consulted with FDA on the appropriate timelines, FDA claimed that the INAD, and thereby the testing phase, was not effective until August 4, 2011 because no NCIE was submitted until then. Thus, the Agency concluded, the June 2011 date should stand. FDA’s PTE regulations at 21 C.F.R. While Nissan et al.

article thumbnail

Jennifer Newberger Returns to HPM as a Director After Stints with Apple, Abbott Laboratories, and Cognito Therapeutics

FDA Law Blog

Jennifer’s combination of experiences as in-house counsel for both large and start-up companies as well as outside counsel provides clients invaluable expertise and problem-solving skills. Jennifer was with the firm from 2011-2017, before leaving for in-house roles at Apple, Abbott Laboratories, and Cognito Therapeutics.